Allogene Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript
Very good afternoon. Thank you very much for joining us at the Goldman Sachs 2022 Healthcare Conference (inaudible) To start the call, can you highlight the overview (inaudible) the progress in general across the (inaudible) portfolio (inaudible).
Thank you, Salveen. First of all, thanks -- thank you very much for joining us here. (inaudible) Great to see you. (inaudible)
(inaudible) system and as for last 4 years. Finally, at the company, it's really based on taking the allogeneic assets from Pfizer (inaudible) patient platform that's based on ALLO-647, our anti-CD52 antibody, and generating the proof of concept.
The proof of concept here really is not only getting the deep responses but also demonstrating the durability of the response. So probably a highlight coming from our most advanced program, ALLO-501A, which we are planning to initiate the pivotal study. Relatively soon,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |